



SYNTHESIS AND CHARACTERIZATION OF FLUOROPYRIMIDINE DERIVATIVES

V. N. Joshi^{1*}, K. A. Joshi², V. A. Modhavadiya³

^{1,2}DKV Arts and Science College, Jamnagar, Gujarat, India.

³M. M. Science College, Morbi, Gujarat, India.

*Corresponding Author: V. N. Joshi

DKV Arts and Science College, Jamnagar, Gujarat, India.

Article Received on 25/09/2017

Article Revised on 16/10/2017

Article Accepted on 06/10/2017

ABSTRACT

A uncomplicated and well-organized method for synthesis of pyrimidine derivatives was achieved from *N*-(substitutedphenyl)-4-methyl-3-oxopentanamide, 4-(5-fluoro-2-methoxypyrimidin-4-yloxy)benzaldehyde and 2-amino-benzimidazole refluxed with *N,N'*-dimethylformamide with high yield and no further purification (Column purification) requirement for compound. FTIR, ¹H NMR and mass spectral data supported the structure of all synthesized compound.


KEYWORDS: *N*-(substitutedphenyl)-4-methyl-3-oxopentanamide, 4-(5-fluoro-2-methoxypyrimidin-4-yloxy)benzaldehyde, 2-amino-benzimidazole.

INTRODUCTION

At that time pyrimidine derivatives most important research in the world like that of triazolopyrimidine is very imperative work of pyrimidine derivatives part because its biological activity like anti-microbial, anti-cancer, anti-HIV, anti-hypertensive, cardiac stimulant, anti-malarial, anti-fungal, anti-HBV, anti-microbial, anti-cancer, anti-pyretic, analgesic, anti-inflammatory, potential herbicidal, and leishmanicidal(1-21). And here new heterocyclic compounds and novel methods for their synthesis is a major topic in contemporary medicinal

chemistry(22-26). Cevipabulin and its analogs represent a class of triazolo[1,5-*a*]pyrimidines and were proved to be potent anti-cancer agents with a unique mechanism of action in promoting tubulin polymerization.

We have developed a new moiety for the synthesis 4(4-(5-fluoro-2-methoxypyrimidin-4-yloxy)phenyl)-2-methyl-*N*-(substitutedphenyl)-1,4-dihydropyrimido-[1,2-*a*]benzimidazole-3-carboxamide (**4a-j**) with the advantage of fine yield and environmentally lenience (**Scheme-a**).



METHOD AND MATERIAL

To the mixture of *N*-(substitutedphenyl)-4-methyl-3-oxopentanamide, 4-(5-fluoro-2-methoxypyrimidin-4-yloxy)benzaldehyde and 2-amino-benzimidazole in few drops of DMF with stirring and heating at 1Hrs. After reaction complete so the add methanol/ethanol and filter solid product.

RESULTS AND DISCUSSION

N-(4-chlorophenyl)-2-isopropyl-4-(4-(5-fluoro-2-methoxypyrimidin-4-yloxy)phenyl)-1,4-dihydropyrimido-[1,2-*a*]benzimidazole-3-carboxamide (**4a**)

Yield: 60%; mp 223°C; Anal. Calcd. for C₃₁H₂₆ClFN₆O₃: C, 63.64; H, 4.48; Cl, 6.06; F, 3.25; N, 14.37; O, 8.20;

Found: C, 63.67; H, 4.40; Cl, 6.07; F, 3.21; N, 14.30; O, 8.25 %; IR (cm⁻¹): 3323 (N-H stretching of amide), 3100 (C-H stretching of aromatic ring), 2985 (C-H asymmetrical stretching of CH₃ group), 2831 (C-H symmetrical stretching of CH₃ group), 1631 (C=O stretching of amide), 1585, 1562 (C=O stretching of cyclic) 1510 (N-H deformation of pyrimidine ring), 1450 (C-H asymmetrical deformation of CH₃ group), 1381 (C-H symmetrical deformation of CH₃ group), 1290 (C-N-C stretching vibration of pyrimidine ring), 1269 (C-O-C asymmetrical stretching of OCH₃), 1076 (C-F stretching), 775 (para-substituted), 725 (C-H in out plane deformation of aromatic ring); ¹H NMR (DMSO-d₆) δ ppm: 2.17-2.22 (s, 6H, H), 3.34 (m, 1H, H), 3.66 (s, 3H, H), 6.57 (s, 1H, H), 7.04-7.07 (dd', 4H, H), 7.23-7.30 (dd', 4H, H), 7.37-7.40 (dd', 4H, H), 7.68 (s, 2H, H), 8.57 (s, 1H, H); MS: m/z 585.

***N*-(4-fluorophenyl)-2-isopropyl-4-(4-(5-fluoro-2-methoxy)pyrimidin-4-yloxy)phenyl)-1,4-dihydropyrimido-[1,2-a]benzimidazole-3-carboxamide (4b)**

Yield: 67%; mp 199°C; Anal. Calcd. for C₃₁H₂₆F₂N₆O₃: C, 65.49; H, 4.61; F, 6.68; N, 14.78; O, 8.44; Found: C, 65.48; H, 4.67; F, 6.69; N, 14.70; O, 8.40%; IR (cm⁻¹): 3333 (N-H stretching of amide), 3108 (C-H stretching of aromatic ring), 2980 (C-H asymmetrical stretching of CH₃ group), 2838 (C-H symmetrical stretching of CH₃ group), 1631 (C=O stretching of amide), 1585, 1562 (C=O stretching of cyclic) 1510 (N-H deformation of pyrimidine ring), 1450 (C-H asymmetrical deformation of CH₃ group), 1381 (C-H symmetrical deformation of CH₃ group), 1290 (C-N-C stretching vibration of pyrimidine ring), 1269 (C-O-C asymmetrical stretching of OCH₃), 1076 (C-F stretching), 775 (para-substituted), 725 (C-H in out plane deformation of aromatic ring); ¹H NMR (DMSO-d₆) δ ppm: 2.17-2.22 (s, 6H, H), 3.34 (m, 1H, H), 3.66 (s, 3H, H), 6.57 (s, 1H, H), 7.04-7.07 (dd', 4H, H), 7.23-7.30 (dd', 4H, H), 7.37-7.40 (dd', 4H, H), 7.68 (s, 2H, H), 8.57 (s, 1H, H); MS: m/z 569.

***N*-(4-bromophenyl)-2-isopropyl-4-(4-(5-fluoro-2-methoxy)pyrimidin-4-yloxy)phenyl)-1,4-dihydropyrimido-[1,2-a]benzimidazole-3-carboxamide (4c)**

Yield: 57%; mp 227°C; Anal. Calcd. for C₃₁H₂₆BrFN₆O₃: C, 59.15; H, 4.16; Br, 12.69; F, 3.02; N, 13.35; O, 7.63; Found: C, 59.15; H, 4.14; Br, 12.68; F, 3.07; N, 13.30; O, 7.60%; IR (cm⁻¹): 3330 (N-H stretching of amide), 3102 (C-H stretching of aromatic ring), 2984 (C-H asymmetrical stretching of CH₃ group), 2848 (C-H symmetrical stretching of CH₃ group), 1631 (C=O stretching of amide), 1588, 1566 (C=O stretching of cyclic) 1515 (N-H deformation of pyrimidine ring), 1452 (C-H asymmetrical deformation of CH₃ group), 1381 (C-H symmetrical deformation of CH₃ group), 1290 (C-N-C stretching vibration of pyrimidine ring), 1267 (C-O-C asymmetrical stretching of OCH₃), 1079 (C-F stretching), 775 (para-substituted), 725 (C-H in out plane deformation of aromatic ring); ¹H NMR (DMSO-d₆) δ

ppm: 2.17-2.22 (s, 6H, H), 3.34 (m, 1H, H), 3.66 (s, 3H, H), 6.57 (s, 1H, H), 7.04-7.07 (dd', 4H, H), 7.23-7.30 (dd', 4H, H), 7.37-7.40 (dd', 4H, H), 7.68 (s, 2H, H), 8.57 (s, 1H, H); MS: m/z 629.

***N*-(4-methylphenyl)-2-isopropyl-4-(4-(5-fluoro-2-methoxy)pyrimidin-4-yloxy)phenyl)-1,4-dihydropyrimido-[1,2-a]benzimidazole-3-carboxamide (4d)**

Yield: 60; mp 221°C; Anal. Calcd. for C₃₂H₂₉FN₆O₃: C, 68.07; H, 5.18; F, 3.36; N, 14.88; O, 8.50; Found: C, 68.03; H, 5.14; F, 3.34; N, 14.84; O, 8.54%; IR (cm⁻¹): 3326 (N-H stretching of amide), 3107 (C-H stretching of aromatic ring), 2984 (C-H asymmetrical stretching of CH₃ group), 2845 (C-H symmetrical stretching of CH₃ group), 1635 (C=O stretching of amide), 1582, 1569 (C=O stretching of cyclic) 1518 (N-H deformation of pyrimidine ring), 1454 (C-H asymmetrical deformation of CH₃ group), 1386 (C-H symmetrical deformation of CH₃ group), 1290 (C-N-C stretching vibration of pyrimidine ring), 1266 (C-O-C asymmetrical stretching of OCH₃), 1079 (C-F stretching), 775 (para-substituted), 725 (C-H in out plane deformation of aromatic ring); ¹H NMR (DMSO-d₆) δ ppm: 2.17-2.22 (s, 6H, H), 3.34 (m, 1H, H), 3.66 (s, 3H, H), 6.57 (s, 1H, H), 7.04-7.07 (dd', 4H, H), 7.23-7.30 (dd', 4H, H), 7.37-7.40 (dd', 4H, H), 7.68 (s, 2H, H), 8.57 (s, 1H, H), 2.30 (s, 3H, H); MS: m/z 565.

***N*-(4-nitrophenyl)-2-isopropyl-4-(4-(5-fluoro-2-methoxy)pyrimidin-4-yloxy)phenyl)-1,4-dihydropyrimido-[1,2-a]benzimidazole-3-carboxamide (4e)**

Yield: 50; mp 220°C; Anal. Calcd. for C₃₁H₂₆FN₇O₅: C, 62.52; H, 4.40; F, 3.19; N, 16.46; O, 13.43; Found: C, 62.52; H, 4.40; F, 3.19; N, 16.46; O, 13.43%; IR (cm⁻¹): 3320 (N-H stretching of amide), 3096 (C-H stretching of aromatic ring), 2980 (C-H asymmetrical stretching of CH₃ group), 2827 (C-H symmetrical stretching of CH₃ group), 1621 (C=O stretching of amide), 1583, 1558 (C=O stretching of cyclic) 1505 (N-H deformation of pyrimidine ring), 1442 (C-H asymmetrical deformation of CH₃ group), 1378 (C-H symmetrical deformation of CH₃ group), 1289 (C-N-C stretching vibration of pyrimidine ring), 1261 (C-O-C asymmetrical stretching of OCH₃), 1071 (C-F stretching), 775 (para-substituted), 725 (C-H in out plane deformation of aromatic ring); ¹H NMR (DMSO-d₆) δ ppm: 2.17-2.22 (s, 6H, H), 3.34 (m, 1H, H), 3.66 (s, 3H, H), 6.57 (s, 1H, H), 7.04-7.07 (dd', 4H, H), 7.23-7.30 (dd', 4H, H), 7.37-7.40 (dd', 4H, H), 7.68 (s, 2H, H), 8.57 (s, 1H, H); MS: m/z 596.

***N*-(3-chlorophenyl)-2-isopropyl-4-(4-(5-fluoro-2-methoxy)pyrimidin-4-yloxy)phenyl)-1,4-dihydropyrimido-[1,2-a]benzimidazole-3-carboxamide (4f)**

Yield: 61%; mp 201°C; Anal. Calcd. for C₃₁H₂₆ClFN₆O₃: C, 63.64; H, 4.48; Cl, 6.06; F, 3.25; N, 14.37; O, 8.20; Found: C, 63.64; H, 4.44; Cl, 6.07; F, 3.24; N, 14.34; O, 8.24 %; IR (cm⁻¹): 3327 (N-H stretching of amide), 3104

(C-H stretching of aromatic ring), 2983 (C-H asymmetrical stretching of CH₃ group), 2835 (C-H symmetrical stretching of CH₃ group), 1628 (C=O stretching of amide), 1576, 1560 (C=O stretching of cyclic) 1509 (N-H deformation of pyrimidine ring), 1449 (C-H asymmetrical deformation of CH₃ group), 1377 (C-H symmetrical deformation of CH₃ group), 1294 (C-N-C stretching vibration of pyrimidine ring), 1265 (C-O-C asymmetrical stretching of OCH₃), 1077 (C-F stretching), 775 (para-substituted), 725 (C-H in out plane deformation of aromatic ring); ¹H NMR (DMSO-d₆) δ ppm: 2.17-2.22 (s, 6H, H), 3.34 (m, 1H, H), 3.66 (s, 3H, H), 6.57 (s, 1H, H), 7.04-7.07 (dd', 4H, H), 7.23-7.30 (dd', 4H, H), 7.37-7.40 (dd', 4H, H), 7.68 (s, 2H, H), 8.57 (s, 1H, H); MS: m/z 585.

***N*-(2-chlorophenyl)-2-isopropyl-4-(4-(5-fluoro-2-methoxy)pyrimidin-4-yloxyphenyl)-1,4-dihydropyrimido-[1,2-a]benzimidazole-3-carboxamide (4g)**

Yield: 51%; mp 187°C; Anal. Calcd. for C₃₁H₂₆ClFN₆O₃: C, 63.64; H, 4.48; Cl, 6.06; F, 3.25; N, 14.37; O, 8.20; Found: C, 63.61; H, 4.45; Cl, 6.01; F, 3.24; N, 14.35; O, 8.28 %; IR (cm⁻¹): 3331 (N-H stretching of amide), 3092 (C-H stretching of aromatic ring), 2988 (C-H asymmetrical stretching of CH₃ group), 2837 (C-H symmetrical stretching of CH₃ group), 1637 (C=O stretching of amide), 1589, 1568 (C=O stretching of cyclic) 1518 (N-H deformation of pyrimidine ring), 1458 (C-H asymmetrical deformation of CH₃ group), 1391 (C-H symmetrical deformation of CH₃ group), 1298 (C-N-C stretching vibration of pyrimidine ring), 1276 (C-O-C asymmetrical stretching of OCH₃), 1089 (C-F stretching), 775 (para-substituted), 725 (C-H in out plane deformation of aromatic ring); ¹H NMR (DMSO-d₆) δ ppm: 2.17-2.22 (s, 6H, H), 3.34 (m, 1H, H), 3.66 (s, 3H, H), 6.57 (s, 1H, H), 7.04-7.07 (dd', 4H, H), 7.23-7.30 (dd', 4H, H), 7.37-7.40 (dd', 4H, H), 7.68 (s, 2H, H), 8.57 (s, 1H, H); MS: m/z 585.

***N*-(3-fluorophenyl)-2-isopropyl-4-(4-(5-fluoro-2-methoxy)pyrimidin-4-yloxyphenyl)-1,4-dihydropyrimido-[1,2-a]benzimidazole-3-carboxamide (4h)**

Yield: 60%; mp 193°C; Anal. Calcd. for C₃₁H₂₆F₂N₆O₃: C, 65.49; H, 4.61; F, 6.68; N, 14.78; O, 8.44; Found: C, 65.40; H, 4.64; F, 6.64; N, 14.74; O, 8.44%; IR (cm⁻¹): 3318 (N-H stretching of amide), 3098 (C-H stretching of aromatic ring), 2994 (C-H asymmetrical stretching of CH₃ group), 2840 (C-H symmetrical stretching of CH₃ group), 1621 (C=O stretching of amide), 1579, 1573 (C=O stretching of cyclic) 1517 (N-H deformation of pyrimidine ring), 1459 (C-H asymmetrical deformation of CH₃ group), 1388 (C-H symmetrical deformation of CH₃ group), 1294 (C-N-C stretching vibration of pyrimidine ring), 1279 (C-O-C asymmetrical stretching of OCH₃), 1065 (C-F stretching), 775 (para-substituted), 725 (C-H in out plane deformation of aromatic ring); ¹H NMR (DMSO-d₆) δ ppm: 2.17-2.22 (s, 6H, H), 3.34 (m, 1H, H), 3.66 (s, 3H, H), 6.57 (s, 1H, H), 7.04-7.07 (dd',

4H, H), 7.23-7.30 (dd', 4H, H), 7.37-7.40 (dd', 4H, H), 7.68 (s, 2H, H), 8.57 (s, 1H, H); MS: m/z 569.

***N*-(3-bromophenyl)-2-isopropyl-4-(4-(5-fluoro-2-methoxy)pyrimidin-4-yloxyphenyl)-1,4-dihydropyrimido-[1,2-a]benzimidazole-3-carboxamide (4i)**

Yield: 53%; mp 201°C; Anal. Calcd. for C₃₁H₂₆BrFN₆O₃: C, 59.15; H, 4.16; Br, 12.69; F, 3.02; N, 13.35; O, 7.63; Found: C, 59.10; H, 4.10; Br, 12.69; F, 3.09; N, 13.38; O, 7.64%; IR (cm⁻¹): 3328 (N-H stretching of amide), 3106 (C-H stretching of aromatic ring), 2984 (C-H asymmetrical stretching of CH₃ group), 2848 (C-H symmetrical stretching of CH₃ group), 1631 (C=O stretching of amide), 1588, 1566 (C=O stretching of cyclic) 1515 (N-H deformation of pyrimidine ring), 1452 (C-H asymmetrical deformation of CH₃ group), 1381 (C-H symmetrical deformation of CH₃ group), 1290 (C-N-C stretching vibration of pyrimidine ring), 1267 (C-O-C asymmetrical stretching of OCH₃), 1079 (C-F stretching), 775 (para-substituted), 725 (C-H in out plane deformation of aromatic ring); ¹H NMR (DMSO-d₆) δ ppm: 2.17-2.22 (s, 6H, H), 3.34 (m, 1H, H), 3.66 (s, 3H, H), 6.57 (s, 1H, H), 7.04-7.07 (dd', 4H, H), 7.23-7.30 (dd', 4H, H), 7.37-7.40 (dd', 4H, H), 7.68 (s, 2H, H), 8.57 (s, 1H, H); MS: m/z 629.

***N*-(2-fluorophenyl)-2-isopropyl-4-(4-(5-fluoro-2-methoxy)pyrimidin-4-yloxyphenyl)-1,4-dihydropyrimido-[1,2-a]benzimidazole-3-carboxamide (4j)**

Yield: 55%; mp 179°C; Anal. Calcd. for C₃₁H₂₆F₂N₆O₃: C, 65.49; H, 4.61; F, 6.68; N, 14.78; O, 8.44; Found: C, 65.47; H, 4.64; F, 6.69; N, 14.74; O, 8.40%; IR (cm⁻¹): 3325 (N-H stretching of amide), 3098 (C-H stretching of aromatic ring), 2989 (C-H asymmetrical stretching of CH₃ group), 2839 (C-H symmetrical stretching of CH₃ group), 1645 (C=O stretching of amide), 1593, 1576 (C=O stretching of cyclic) 1500 (N-H deformation of pyrimidine ring), 1443 (C-H asymmetrical deformation of CH₃ group), 1377 (C-H symmetrical deformation of CH₃ group), 1296 (C-N-C stretching vibration of pyrimidine ring), 1275 (C-O-C asymmetrical stretching of OCH₃), 1084 (C-F stretching), 775 (para-substituted), 725 (C-H in out plane deformation of aromatic ring); ¹H NMR (DMSO-d₆) δ ppm: 2.17-2.22 (s, 6H, H), 3.34 (m, 1H, H), 3.66 (s, 3H, H), 6.57 (s, 1H, H), 7.04-7.07 (dd', 4H, H), 7.23-7.30 (dd', 4H, H), 7.37-7.40 (dd', 4H, H), 7.68 (s, 2H, H), 8.57 (s, 1H, H); MS: m/z 569.

CONCLUSION

In loftiness, we include syntheses of narrative pyrimidine derivatives using appropriate and trouble-free method. This method produces these products in supreme yields and difficulty-free workup. The isolated products are unadulterated and no need of further purification.

ACKNOWLEDGEMENTS

Authors are very thankful to Dr. A. H. Raval (Principle, D. K. V. arts and science college, Jamnagar.), Dr. S. N. Joshi (Head, Department of chemistry, D. K. V. arts and science college, Jamnagar.), Dr. P. S. Oza (Assistance Professor, D. K. V. arts and science college, Jamnagar.) and Dr. M. V. Parsania (Associate Professor, M. M. Science College, Morbi) for there encouragement and moral support during my work.

REFERENCES

1. Fischer G. *et al.*; Adv. Heterocycl. Chem, 2008; 95: 143.
2. Gujjar R., Marwaha A., El Mazouni F., White J., White K.L., Creason S., Shackleford D. *et al.*; J. Med. Chem, 2009; 52: 1864.
3. Chen Q., Zhu X. L., Jiang L.L., Liu Z. M., Yang G. F.; Eur. J. Med. Chem, 2008; 43: 595.
4. Yu W., Goddard C., Clearfield E., Mills C., Xiao T., Guo H., Morrey J. D. *et al.*; J. Med. Chem, 2011; 54: 5660.
5. El-Gendy M. M. A., Shaaban M., Shaaban K.A., El-Bondkly A.M., Laatsch H.; J. Antibiot, 2008; 61: 149.
6. Allen J. G., Bourbeau M. P., Wohlhieter G. E., Bartberger M. D., Michelsen K., Hungate R., Gadwood R. C. *et al.*; J. Med. Chem, 2009; 52: 7044.
7. Tang W., Shi D. Q.; J. Hetero. Chem., 2010; 47: 162.
8. Chen Q., Liu Z. M., Chen C. N., Jiang L. L., Yang G. F.; Chem. Biodivers, 2009; 6: 1254.
9. El-Koussi N. A., Omar F. A., Abdel-Aziz S. A., Radwan M. F.; Bull. Pharm. Sci., 2004; 27: 141.
10. Lakomska I., Wojtczak A., Sitkowski J., Kozerski L., Szlyk E.; Polyhedron, 2008; 27: 2765.
11. Lakomska I. *et al.*; Inorg. Chim. Acta, 2009; 362: 669.
12. R. Trivedi, B. H. Dholariya, C. P. Vakhariya, D. K. Dodiya, H. K. Ram, V. B. Kataria, A. B. Siddiqui & V. H. Shah; Medicinal Chemistry Research, 2011; 19(7): 617-716.
13. K. Ahir, H. Ram, D. Dodiya and V. Shah; Journal of Chemical and Pharmaceutical Research, 2013; 5(6): 113-116.
14. R. S. Pada, R. N. Nandaniya, H. K. Ram and V. H. Shah; Journal of Chemical and Pharmaceutical Research, 2012(7): 3557-3561.
15. H. K. Ram, K. A. Joshi, K. Vyas and K. Nimavat; Journal of Chemical and Pharmaceutical Research, 2012; 4(4): 2133-2137.
16. M. Borisagar, K. A. Joshi, H. K. Ram, K. Vyas And K. Nimavat; ActaChim. Pharm. Indica, 2012; 2(2): 101-105.
17. K. A. Joshi and H. K. Ram; International Journal of Applied Chemistry (UGC Approved-MRP work), 2017; 13(1): 135-140.
18. J. H. Vora, K. A. Joshi, H. K. Ram and K. L. Karangia; European Journal of Biomedical and Pharmaceutical sciences, 2015; 2(2): 155-162.
19. N. Chauhan, K. Vyas, K. Nimavat, K. A. Joshi; Journal of Chemical and Pharmaceutical Research, 2012; 4(2): 1106-1110.
20. Patel K. N., Joshi K. A., Ram H. K.; International Journal for Pharmaceutical Research Scholars (IJPRS), 2015; 4: 210-214.
21. Vora J. H., Joshi K. A., Ram H. K.; International Journal for Pharmaceutical Research Scholars (IJPRS), 2015; 4: 163-167.
22. Mohamed A. M., El-Sayed W. A., Alsharari M. A.; Al-Qalawi H.R.M., Germoush M.O.: Arch. Pharm. Res., 2013; 36: 1055.
23. Mohamed A.M., Amr A.E., Alsharari M.A.; AlQalawi H.R.M., Germoush M.O., Al-Omar M.A.: Am. J.; Biochem. Biotechnol, 2011; 7: 43.
24. Abd El-Salam O.I., Fahmy A.F.M., Mohamed A.M., Elnaggar D.H., Hammam A.G.; World J. Chem., 2010; 5: 07.
25. Hammam A.G., Abd El-Salam O.I., Mohamed A.M., Abdel-Hafez A.; Indian J. Chem, 2005; 44B: 1887.
26. Karangiya K L., Upadhyay J. J., IJPSDR, 2016; 8(2): 98-102.